

Preliminary Results of Public Joint Shareholders Company (Final Result Brief for the year ended 31 December 2023)

First - General Information:

Name of the company: Gulf Pharmaceutical Industries PSC (Julphar)

Date Establishment: 1980

Paid up capital: 1,155,227,811

Subscribed capital: 1,155,227,811

Authorized capital: 1,155,227,811

Chairman of the Board: Sheikh Saqer Bin Humaid Al Qassimi

Chief Executive Officer: Basel Nimer Ali Ziyadeh

Name of the external auditor: M/s Ernst & Young

Mailing address: P.O. Box 997

Tel: +971 7 246 1461

Fax: +971 7246 2462

E – mail: julphar@emirates.net.ae

Second - Preliminary Results (000 AED):

	<u>2023</u>	<u>2022</u>
Total Assets	2,451,800	2,399,400
Shareholders Equity	792,900	916,500
Revenues	1,638,100	1,616,100
EBITDA from continuing operations	111,200	144,600
Net Operating Profit/(loss)	(30,700)	12,600
Net loss for the year	(103,100)	(31,700)
Earnings per share (fils per share)	(8.7)	(2.5)


Summary of the company's performance for the last fiscal year.

Amid the macroeconomic challenges, Julphar's revenue showed a growth of 1.4%, reaching 1,638.1 mAED for the year 2023 (+2.9% at constant currency), supported by the strong development in GCC while navigating headwinds in our operations in Egypt.

The Group's EBITDA from continuing operations reached 111.2 mAED (6.8% of Net Sales) and 124.1 mAED (7.6% of Net Sales) when adjusting from one-off events related to impairment of overdue receivables of Lebanon business and other one-time events.

During the reporting period, Julphar made significant progress in its efforts to invest in the product pipelines of its core business areas and bring onboard operational improvements to generate efficiencies and contain cost.

Julphar is committed to providing the most affordable and highest quality health care solutions in the MENA region.

The name of the chairman of the company or the authorized signatory	Sheikh Saqer Bin Humaid Al Qassimi
Signature and Date	13/02/2024 
Company's Seal	